Yuan Z, Li W-T, Ye X-D, Zhu H-Y, Peng W-J
Department of Radiology, Shanghai PLA No. 85 Hospital, 1328 Hua Shan Road, Shanghai, 200052, People's Republic of China,
Clin Transl Oncol. 2014 Jul;16(7):599-605. doi: 10.1007/s12094-013-1147-5. Epub 2013 Dec 20.
The established and adapted image biomarkers based on size for tumor burden measurement continue to be applied to hepatocellular carcinoma (HCC) as size measurement can easily be used in clinical practice. However, in the setting of novel targeted therapies and liver directed treatments, simple tumor anatomical changes can be less informative and usually appear later than biological changes. Functional magnetic resonance imaging (MRI) has a potential to be a promising technique for assessment of HCC response to therapy. In this review, we discuss various functional MRI biomarkers that play an increasingly important role in evaluation of HCC response after treatment.
基于大小用于测量肿瘤负荷的既定和适应性图像生物标志物继续应用于肝细胞癌（HCC），因为大小测量在临床实践中易于使用。然而，在新型靶向治疗和肝脏定向治疗的背景下，简单的肿瘤解剖学变化可能信息量较少，且通常比生物学变化出现得更晚。功能磁共振成像（MRI）有可能成为评估HCC治疗反应的一种有前景的技术。在本综述中，我们讨论了各种功能MRI生物标志物，它们在评估HCC治疗后的反应中发挥着越来越重要的作用。
